ASTCT Resources for COVID-19
ASTCT Headquarters is closely monitoring the developing news about the Coronavirus (COVID-19) from the World Health Organization (WHO), Centers for Disease Control (CDC), and our community. We want you to know that we are placing the highest priority on the health and safety of all of our members and their patients and we will make decisions moving forward with the input of public health officials.
Members of ASTCT's Infectious Disease SIG have developed interim guidelines for COVID-19 management of HCT and cellular therapy patients. These guidelines will be modified as new information becomes available, including more data on epidemiology and clinical outcomes, and efficacy of drug therapies including clinical trial outcomes of novel therapeutics. Click here to view updated guidelines.
ASH-ASTCT COVID 19 Vaccine FAQs
The ASH-ASTCT COVID-19 Vaccination for HCT and CAR T cell recipients: Frequently Asked Questions have been updated to include information on the Johnson & Johnson/Janssen vaccine. The document which was updated on 4/1/2021 can be found here.
The authors of the FAQs are a team of experts representing both ASH and ASTCT. The team met several times and work together to develop this document which will be updated periodically when new data become available. All current guidances are based on opinions of the ASTCT/ASH COVID-19 Vaccine expert panel. Furthermore, the expert panel recognizes that vaccine supply varies between states due to federal and state allocation, and our opinion is not meant to supersede vaccine eligibility as determined by the state or federal government.
Contributors to the FAQs document are: Fareed Khawaja, Roy F Chemaly, Sanjeet Dadwal, Steve Pergam, John Wingard, Jeffery Auletta, Zeinab El Boghdadly, Maheen Abidi, Alpana Waghmare, Zainab Shahid, Ingrid Pabinger-Fasching, Laura Michaels, Joshua Hill, Tobias M. Hohl, Mini Kamboj, Genovefa Papanicolaou, Michael Boeckh
Event Updates and Webinars
As this is an evolving situation, we will keep our website updated with the latest news and information related to all of our upcoming events. Additionally, due to travel restrictions related to COVID-19, some speakers at upcoming meetings will be required to present their sessions virtually. If you have any questions or concerns regarding your attendance at events, you may direct them to firstname.lastname@example.org.
ASTCT is in the process of developing additional educational webinars to share updates and resources. Click here to view upcoming COVID-19 related content. Recordings of past webinars can be found here.
News and Updates
ASTCT and CIBMTR have issued a joint press release on guidelines and measures for combating COVID-19 and protecting transplant patients. Read it here.
In addition to our educational resources, please visit NUCLEUS or this community's blog for more information and updates.
As we receive additional patient guidelines, updates from the CDC or WHO, or policy updates, that information will be posted to the resource library within this community.
CIBMTR Data Reporting for COVID-19: In an effort to inform centers, clinicians and patients about the impact of the pandemic on transplant and cellular therapy recipients, CIBMTR has made several alterations to forms and reporting to facilitate collection and dissemination of data on COVID-19 infections. See CIBMTR website for more details: www.cibmtr.org
The Transplant Associated Learning Network Team (TALNT) has an international COVID-19 Working Group used to aid in the exchange of institutional practices and resources regarding the current COVID-19 pandemic. If you are interested in joining this network, please email Hannah Ingraham at Hannah.email@example.com.
You can use the discussion forum within this community to connect and share information and updates from within your institution.